

08 October 2025

Dermatology and Respiratory medicine

How many patients were treated in September 2025 (or latest available month) by the Dermatology department with the following drugs:

• Abrocitinib (Cibinqo)	<5
• Baricitinib (Olmiant)	<5
• Dupilumab (Dupixent)	62
• Lebrikizumab (Ebglyss)	<5
• Omalizumab (Xolair)	10
• Tralokinumab (Adtralza)	<5
• Upadacitinib (Rinvoq)	10
• Nemolizumab (Nemluvio)	<5

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.

How many patients were treated in September 2025 (or latest available month) by the Respiratory Medicine departments with the following drugs:

• Benralizumab (Fasenra)	121
• Dupilumab (Dupixent)	58
• Mepolizumab (Nucala)	267
• Omalizumab (Xolair)	24
• Reslizumab (Cinqaero)	0
• Tezepelumab (Tezspire)	96